Atrium Therapeutics Inc. (RNA)
The price, the headline numbers and the latest news, in one place.
Atrium Therapeutics Inc. (RNA) Stock Price, Analysis & Data
| Bid | 9.9 |
| Market Cap | 230.58M |
| Revenue (ttm) | 35.84M |
| Net Income (ttm) | -65.99M |
| n/a | |
| -5.44 | |
| n/a | |
| -1.67 | |
| P/B (ttm) | 0.98 |
| P/S (ttm) | 6.43 |
| Earnings Date | May 11, 2026 |
| Ask | 16.98 |
| Volume | 218,805 |
| Avg. Volume (20D) | 193,680 |
| Open | 13.75 |
| Previous Close | 13.71 |
| Day's Range | 13.20 - 13.88 |
| 52-Week Range | 11.13 - 16.77 |
| Analyst | Strong Buy |
| Price Target | 25 (85.46%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About RNA
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipe...
Financial Performance
In 2025, Atrium Therapeutics's revenue was 18.62M, an increase of 70.85% compared to the previous year's 10.9M. Earnings were -76.68M, an increase of 205.25%.
Financial StatementsAnalyst Forecast
According to 4 analyst ratings, the average rating for RNA stock is "Strong Buy". The 12-month stock price forecast is 25, which is upside of 85.46% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
